Cargando…

Expanding Footprints of Biosimilar Tenecteplase

Detalles Bibliográficos
Autores principales:	Subhash, Yada, Praveen K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394453/ https://www.ncbi.nlm.nih.gov/pubmed/37538426 http://dx.doi.org/10.4103/aian.aian_256_23

Ejemplares similares

Trail Toward Tenecteplase
por: Srivastava, Trilochan, et al.
Publicado: (2022)

Is Tenecteplase a Viable Alternative to Alteplase in the Treatment of Acute Ischemic Stroke?
por: Vaishnav, Anand Girish
Publicado: (2022)

Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?
por: Zitek, Tony, et al.
Publicado: (2020)

Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study
por: Mohan, Ayush, et al.
Publicado: (2023)

Switching to Tenecteplase from Alteplase for Ischemic Stroke: Is it the Time for Universal Adoption?
por: Kharel, Sanjeev, et al.
Publicado: (2022)

Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse(®)) with those of an alleged biosimilar
por: Kliche, Werner, et al.
Publicado: (2014)

The Expanding Global Footprint of Burkholderia pseudomallei and Melioidosis
por: Currie, Bart J., et al.
Publicado: (2023)

Deciphering the Footprints of Autoimmunity in CNS Demyelinating Disorders
por: Netravathi, M
Publicado: (2022)

Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns
por: Dong, Yi, et al.
Publicado: (2021)

Replacing Alteplase with Tenecteplase: Is the Time Ripe?
por: Singh, Nishita, et al.
Publicado: (2023)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Diet for a small footprint
por: Keesing, Felicia
Publicado: (2022)

Commentary: Biosimilars in the treatment of retinopathy of prematurity
por: Soni, Tanvi, et al.
Publicado: (2023)

Biosimilar and interchangeable: Inseparable scientific concepts?
por: de Mora, Fernando, et al.
Publicado: (2019)

Interchangeability of Biosimilars: Overcoming the Final Hurdles
por: Barbier, Liese, et al.
Publicado: (2021)

Intracoronary tenecteplase in STEMI with massive thrombus
por: Jayagopal, P.B., et al.
Publicado: (2018)

Tenecteplase: Haemorrhagic pericarditis: case report
Publicado: (2020)

Tenecteplase Thrombolysis in Posterior Circulation Stroke
por: Alemseged, Fana, et al.
Publicado: (2021)

Tenecteplase in Ischemic Stroke: Challenge and Opportunity
por: Li, Guangshuo, et al.
Publicado: (2022)

Biosimilars: a regulatory perspective from America
por: Kay, Jonathan
Publicado: (2011)

Biomedical and Market Issues Surrounding the Advent of Biosimilars
por: Cline, Abigail, et al.
Publicado: (2016)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke
por: Logallo, Nicola, et al.
Publicado: (2014)

Intrapleural Tenecteplase for Complicated Parapneumonic Pleural Effusion
por: Kadhem, Husain, et al.
Publicado: (2021)

Tenecteplase or Alteplase: What Is the Thrombolytic Agent of the Future?
por: Mahmood, Ammad, et al.
Publicado: (2022)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
por: Cohen, Stanley B, et al.
Publicado: (2023)

Biosimilar Drugs: What Would Be a Reasonable Extrapolation?
por: Gifoni, Markus A.C., et al.
Publicado: (2017)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

The road to biosimilars in rare diseases ‐ ongoing lessons from Gaucher disease
por: Drelichman, Guillermo, et al.
Publicado: (2019)

To See or NOsee: The Debate on the Nocebo Effect and Optimizing the Use of Biosimilars
por: Rezk, Mourad F., et al.
Publicado: (2018)

EU pharmacovigilance regulatory requirements of anticancer biosimilar monoclonal antibodies
por: Francescon, Sara, et al.
Publicado: (2018)

Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns
por: Kumar, Aman, et al.
Publicado: (2021)

Our first footprints
por: The Lancet Child & Adolescent Health
Publicado: (2020)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

Here to Stay: Biosimilars in Hematology
por: Gribben, John, et al.
Publicado: (2019)

Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction
por: Melandri, Giovanni, et al.
Publicado: (2009)

Early Experience With Tenecteplase at a Comprehensive Stroke Center
por: Panezai, Spozhmy, et al.
Publicado: (2021)

Alteplase or tenecteplase for thrombolysis in ischemic stroke: An illustrated review
por: Zhu, Annie, et al.
Publicado: (2022)

Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes
por: Uno, Hajime, et al.
Publicado: (2019)

Biosimilar Drugs for Multiple Sclerosis: An Unmet International Need or a Regulatory Risk?
por: Rivera, Victor M.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h9ejo9fdcsjnmcdhl0fqb7o0ac